A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
Status:
Recruiting
Trial end date:
2024-03-11
Target enrollment:
Participant gender:
Summary
A randomized withdrawal study in which responders to open-label treatment with tofacitinib
will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the
double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects
will be discontinued once they experience sJIA flare. Once 31 flares are reported the study
will be completed.